Eli Lilly CEO Urges PBS Inclusion for Mounjaro, Critiques Australia’s Vaccine Approach

Mounjaro PBS Inclusion: CEO Urges Government Agreement

Mounjaro PBS (Pharmaceutical Benefits Scheme) coverage remains a point of contention for Eli Lilly as the company seeks a sustainable path to make the diabetes and weight loss medication accessible to Australians. As of August 12, 2026, the company continues to advocate for its inclusion on the government-subsidised formulary. According to ABC News, Eli Lilly’s CEO David Ricks has publicly stated his desire to reach a pricing agreement with the Australian government, despite previously walking away from earlier negotiations due to valuation disagreements.

What is Mounjaro and how does it work for diabetes treatment?

Mounjaro is a medication clinically indicated for the treatment of Type 2 diabetes and, more recently, for weight loss management in specific patient populations. It functions as a dual GIP and GLP-1 receptor agonist, which effectively mimics hormones in the body to regulate blood sugar levels and suppress appetite. For patients, this pharmacological approach offers a targeted method to assist with metabolic health, though it is not yet subsidised through the Mounjaro PBS system. The medication has gained significant popularity globally, making it a highly sought-after treatment option for those managing chronic metabolic conditions. Because of its specific mechanism of action, it requires professional medical supervision to ensure it is prescribed correctly based on a patient’s individual health history. In Australia, patients currently must source the drug privately, which can be a substantial out-of-pocket burden for many families managing long-term health requirements.

The drug works by interacting with the body’s natural signaling pathways that control insulin secretion and gastric emptying. By slowing down the digestive process, patients often experience an increased sense of fullness, which supports weight management alongside better glucose control. It is vital that anyone considering this treatment consults with their general practitioner to understand the potential risks and whether it aligns with their specific medical profile. Managing a chronic illness like diabetes is often a significant financial challenge, and patients are encouraged to monitor updates from Services Australia regarding changes to medication coverage. When you are balancing monthly household budgets, the lack of a government subsidy for essential medications can create added stress. It is worth tracking any formal policy developments closely to see if future listings might alleviate these ongoing healthcare costs for the Australian community.

For those living with Type 2 diabetes, the ability to access affordable, modern treatments is a primary concern for long-term health outcomes. Mounjaro offers an alternative to older classes of medication, providing a modern approach that researchers suggest may lead to improved patient adherence. However, the current reality for many Australians is that they must weigh the significant benefits of the drug against the reality of private pricing. It is a common sentiment among patients that healthcare should be accessible, and the ongoing dialogue between global pharmaceutical entities and local authorities plays a critical role in this. As the government continues its reviews, patients are advised to remain in contact with their medical team about current treatment costs. Understanding the clinical guidelines for diabetes management is essential, and your doctor remains the most reliable source for information regarding your specific treatment pathway in 2026.

Why is Eli Lilly pushing for Mounjaro to be included on the PBS?

Eli Lilly is pursuing Mounjaro PBS inclusion because the company believes that the current valuation offered by the Australian government does not adequately reflect the therapeutic benefit of the medication. CEO David Ricks has indicated that previous government proposals were deemed unrealistic and unviable, leading to the pharmaceutical giant walking away from earlier negotiations. The central issue is how Australia values the medicine compared to other global markets where the drug is already reimbursed. For the company, securing a place on the PBS is a strategic necessity to ensure widespread availability for the Australian public, but this requires an alignment on price points that the Australian government has not yet met. The tension highlights the ongoing difficulty in balancing global drug pricing with the budgetary constraints of the domestic health system, leaving patients caught in the middle of these complex international negotiations.

The company maintains that the prices proposed in previous rounds were significantly lower than any other reimbursed price globally, which is the primary driver for their resistance. By continuing to keep the conversation open, Eli Lilly signals that it remains committed to the Australian market, provided that a mutually acceptable commercial agreement can be reached. This stance reflects a broader trend where pharmaceutical companies insist on global pricing parity to ensure the long-term sustainability of their supply chains. For Australian consumers, this situation means that the wait for subsidised access is extended, as both parties remain at an impasse regarding the economic valuation of the drug. The advocacy from the company is intended to push the government toward a new framework that recognises the value of modern diabetes therapies, ultimately aiming to change the landscape for Australian patients who are currently paying the full market price for their essential treatments.

Transparency in these negotiations is rare, yet the public comments from Mr. Ricks have provided a window into the frustration felt by developers of new medicines. When a company feels that a government is undervaluing a breakthrough treatment, it can lead to market delays, as seen in the repeated attempts to get Mounjaro added to the PBS list. This creates a challenging environment for local medical professionals who wish to offer the most effective, up-to-date treatment options to their diabetic patients. Patients are left to manage the rising costs of private prescriptions while waiting for a breakthrough in the policy landscape. It is recommended that patients review their private health insurance options to see if they provide any coverage for non-PBS listed medications, as this can sometimes provide a small buffer against the high retail cost of newer pharmaceutical products in 2026.

What are the potential side effects and risks of using Mounjaro?

Like any potent medication, Mounjaro carries a range of potential side effects that must be carefully managed under the direction of a healthcare provider. Common adverse reactions reported by patients include gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal discomfort as the body adjusts to the therapy. These symptoms are often more pronounced during the initial stages of treatment or following dose escalations. Because of these risks, it is essential for patients to engage in regular monitoring with their doctor to assess how their system is responding to the medication. While many individuals find the medication well-tolerated over time, the personal impact of these side effects can vary significantly. Any persistent or severe symptoms should be reported to a GP immediately to ensure that the medication is still appropriate for the patient’s individual health status and that any necessary clinical adjustments are made promptly.

Beyond the common gastrointestinal side effects, there are specific warnings associated with the use of such medications, particularly regarding the risk of pancreatitis or other metabolic disturbances. Patients with a history of certain endocrine conditions, including medullary thyroid carcinoma, may have specific contraindications that prevent them from using this class of drug. A thorough clinical assessment prior to starting treatment is the most effective way to identify these risks. For those living in Sydney or regional areas across NSW, it is crucial to rely on your local medical practice for advice rather than anecdotal evidence from social media or online forums. The complexity of managing diabetes means that individualised care is non-negotiable for safety. Ensure your doctor is aware of all other supplements or medications you are taking, as drug-to-drug interactions can complicate the safety profile and effectiveness of your treatment regime throughout 2026.

Navigating the risks of a new medication requires a supportive relationship with your health care team, who can provide the necessary context for your unique medical history. For instance, if you are an older patient with multiple comorbidities, the decision to initiate Mounjaro must be weighed against the potential impact on your kidney function or blood pressure. Regular blood tests and follow-up appointments are standard protocols to ensure that the therapeutic benefits outweigh any potential negative side effects. The goal is to achieve metabolic stability while maintaining a high quality of life. Patients are encouraged to document their experiences with any side effects, as this data is invaluable to their GP when deciding on dosage adjustments. By staying proactive, patients can work with their healthcare providers to manage risks effectively and continue their treatment with confidence as more data becomes available in the medical literature.

What is Eli Lilly’s criticism of Australia’s vaccine approach, and how does it relate to Mounjaro?

Eli Lilly’s leadership has expanded the conversation beyond just the Mounjaro PBS pricing by offering broader critiques of Australia’s healthcare and vaccine procurement approach. The CEO suggests that the same issues surrounding how Australia values medical innovation—including vaccines—are reflected in the current struggle to list Mounjaro. By linking these two policy areas, the company is positioning itself as a critic of a health system that it views as being overly focused on cost-minimisation at the expense of early access to new, globally-recognised therapies. This broader perspective serves to highlight a perceived misalignment between the company’s expectations of global value and the local government’s budgetary priorities. For the public, this suggests that the friction regarding Mounjaro is not an isolated event but rather a symptom of a deeper philosophical divide between global pharmaceutical corporations and the Australian health policy environment regarding how to reward and incentivise medical innovation.

This critical stance is significant because it challenges the traditional approach taken by the Pharmaceutical Benefits Advisory Committee (PBAC) during price negotiations. When a company like Eli Lilly expresses dissatisfaction with the vaccine approach or the evaluation of new drugs, it signals a risk that Australia might become less of a priority for the launch of next-generation therapies. If the company continues to feel that its innovations are not being valued appropriately, it may impact the speed at which future treatments reach the Australian market. This is a point of concern for patient advocacy groups that want to see faster adoption of global medical breakthroughs. The CEO’s comments are an attempt to influence the public and policy discourse, framing the negotiation as a matter of ensuring Australia remains competitive in the global health market, rather than just a domestic pricing dispute.

The implication for the Australian healthcare system is that it must continue to refine how it assesses the value of medical innovations to avoid discouraging global investment. While the government is tasked with ensuring taxpayer funds are spent responsibly, there is an inherent risk that overly rigid price caps can lead to the withdrawal of support for new medications. This represents a delicate balancing act that affects everyone from the policy makers in Canberra to the individual patient in a local pharmacy. As the country moves through 2026, the ongoing dialogue around these issues will likely shape the future of medicine access for all Australians. For those keeping an eye on the healthcare industry, understanding the connection between broader drug pricing strategies and specific medication availability provides a clearer picture of why your access to certain life-changing drugs can be subject to such prolonged and complex negotiations.

Who is eligible to access Mounjaro through the PBS?

Currently, Mounjaro is not listed on the PBS, meaning no patient is eligible to access it through the government-subsidised scheme at this time. Access is strictly limited to private prescription pathways, where patients pay the full retail cost set by the pharmaceutical company and the pharmacy. If a future agreement is reached between Eli Lilly and the Australian government, the PBS would likely establish specific criteria for eligibility, similar to other diabetes medications. Historically, such criteria include a clinical diagnosis of Type 2 diabetes and a failure to achieve adequate glucose control on first-line treatments like metformin. Potential eligibility would depend on the final deal negotiated, which may limit the drug to patients with specific blood sugar profiles or those who have exhausted other treatment options before the subsidy is granted to the individual.

For those interested in potential future eligibility, it is recommended to keep records of your current diabetes management, including blood glucose logs and previous medication history. This preparation ensures that if the drug is eventually listed on the Mounjaro PBS, you are ready to discuss your eligibility with your GP immediately. The process for listing a drug is rigorous and involves evaluating both the clinical efficacy and the cost-effectiveness of the treatment for the broader population. Since the government seeks to provide the greatest benefit for the most people, listing is never guaranteed and often comes with strict conditions to ensure the subsidy is used appropriately. Until a decision is made, the financial responsibility for Mounjaro rests entirely with the patient, creating a significant barrier for many middle-income households who may require this medication but find the private price point difficult to manage consistently over time.

Should the drug be added to the PBS in the future, the cost to the patient would be reduced to the standard co-payment amount, which is periodically indexed by the government. Patients should be aware that even if a drug is listed, there can be “authority required” restrictions, meaning your doctor must provide additional clinical information to prove you meet the specific requirements before the subsidy is applied. It is a process that requires patience and clear communication with your pharmacist and GP. By maintaining a good relationship with your medical team, you ensure that you are at the front of the queue if or when the drug becomes subsidised. It is also helpful to stay updated via official health newsletters or your doctor’s clinic announcements, as changes to the PBS formulary are typically announced and implemented on a scheduled basis, keeping the community informed of any new affordable options.

How does Mounjaro compare to other diabetes medications on the PBS?

Mounjaro belongs to a class of medications known as dual GIP/GLP-1 receptor agonists, which distinguishes it from many of the single-receptor medications already available on the PBS. While current PBS-listed treatments, such as traditional metformin or specific GLP-1 agonists, are highly effective at managing blood glucose levels, Mounjaro’s dual action is often described as providing a more robust response for certain patients. Clinically, it aims to deliver both significant glycemic control and weight management benefits in a single weekly injection. Because it works differently than traditional tablet-based therapies, it is often viewed as a next-generation option for those who haven’t seen the desired results from standard, subsidised care. However, the direct comparison remains difficult for patients until it is priced within the same range as other available subsidised options through a formal PBS agreement.

One of the primary benefits touted for Mounjaro is its dual efficacy, which can simplify a patient’s treatment regimen compared to taking multiple medications to manage both diabetes and weight. For patients who find the pill burden of multiple daily medications overwhelming, an injectable therapy that addresses two major aspects of metabolic health can be a positive shift. However, until it is integrated into the PBS, it competes at a disadvantage because patients must pay full price for it while other, albeit different, treatments are heavily subsidised. This cost differential is the main factor preventing many Australians from making the switch to this newer medication. Patients currently have to weigh the potential clinical advantage against the substantial financial cost, which remains the deciding factor for many in their treatment choices in 2026.

Ultimately, the medical community continues to monitor how Mounjaro fits into the standard treatment algorithms for diabetes in Australia. Guidelines suggest that doctors should always start with the most established and cost-effective treatments before moving to newer, more expensive therapies. If Mounjaro is added to the PBS, it would likely be positioned as an option for patients who require more intensive management than what current first-line therapies provide. The goal is to match the patient’s clinical needs with the most effective, accessible treatment possible. As more clinical data becomes available, the professional consensus on where Mounjaro sits relative to existing PBS options will likely become clearer, helping doctors make informed decisions that support both the health and financial wellbeing of their patients over the coming years as new data emerges.

Frequently Asked Questions